FDA Inspection 998259 — Roswell Park Cancer Institute Corporation. Div. Of Pathology
The FDA completed an inspection of Roswell Park Cancer Institute Corporation. Div. Of Pathology on Jan 13, 2017 in Buffalo, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jan 13, 2017
- Fiscal Year
- 2017
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Buffalo, NY (United States)